Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis
Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis have?
Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis has 110 citations in the OpenAlex counts ScholarIQ stores.
When was Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis published?
Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis has 2022 year in the ScholarIQ index.
What is the open-access status of Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis?
Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis has hybrid oa status in the ScholarIQ index.
What is the DOI of Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis?
The DOI for Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis is on the source record.
What is the PMID of Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis?
The PMID for Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis is on the source record.
What is the OpenAlex record for Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis?
The OpenAlex for Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis is on the source record.